Marksans Pharma reported better than street estimates of Q3 results. Company reported Q3 net profit Rs251.3mn (up 44% YoY), EBITDA margin 14.5% vs 13.2% (QoQ) and sales Rs2.48bn (up 14% YoY)
Feedback
MARKSANS 
Reputation: 262 • Feb 11, 2019 1:39 PM
Vote
Comment
Share